trending Market Intelligence /marketintelligence/en/news-insights/trending/cssknwmf8uhaarizg6pt2a2 content esgSubNav
In This List

ASCO conference: Immunomedics breast cancer drug shows 'encouraging activity'

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: Immunomedics breast cancer drug shows 'encouraging activity'

Immunomedics Inc. said its therapy sacituzumab govitecan showed "encouraging activity" in certain patients with advanced breast cancer whose disease progressed despite receiving treatment.

The Chicago-based drugmaker is studying the therapy in a phase 1/2 trial of 54 patients whose disease growth was due to the hormone estrogen, had grown to nearby tissue or other parts of the body, and did not express the HER2 protein on the surface of breast cells that can be overproduced in cancer.

All patients in the study had received at least two prior treatments for metastatic disease, with a median of three hormonal agents and two chemotherapy regimens.

SNL Image

According to data presented at the 2018 American Society of Clinical Oncology meeting, the company's therapy helped shrink the tumor in 31% of patients.

Patients responded to the treatment for 7.4 months, on average. "Women with ER+/HER2– [metastatic breast cancer] who have progressed on endocrine therapies and initial chemotherapy, have very limited treatment options, and sacituzumab govitecan, based on the results presented today, could provide a promising option," Aditya Bardia, who presented the study in an oral session at the 2018 ASCO conference, said in a statement.

Patients generally tolerated the treatment with sacituzumab govitecan well.

According to the National Cancer Institute, about 150,000 women in the U.S. were estimated to be living with metastatic breast cancer in 2017 which spreads to other parts of the body.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on site and an additional 3,350 abstracts to be published online.